Gefapixant, a P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough: a randomised, double-blind, controlled, parallel-group, phase 2b trial
Resource Type
Article
Authors
Smith, Jaclyn ; McGarvey, Lorcan ; Birring, Surinder ; Hull, James ; Carr, Warner W ; Goldsobel, Alan B ; Gross, Gary N ; Holcomb, John R ; Hussain, Iftikhar ; Sher, Mandel ; Spangenthal, Selwyn ; Storms, William ; Morice, Alyn ; Elkayam, David ; Steven, Gary C ; Krainson, James ; Fakih, Faisal Alfonso ; Matz, Jonathan ; Brooks, Gregory Daniel ; Casale, Thomas ; Berman, Gary D ; Condemi, John J ; Greos, Leon S ; Gogate, Shaila U ; Sher, Ellen R ; Friesen, Jason H ; Schenkel, Eric J ; Bernstein, David Isaac ; Corren, Jonathan ; Sundar, Krishna ; Gotfried, Mark H ; Montanaro, Anthony ; Lumry, William R ; Amar, Niran J ; Kaplan, Michael S ; Prenner, Bruce M ; Murphy, Thomas R ; Good, James S ; Parker, Sean ; Harrison, Tim ; Pavord, Ian ; Brightling, Christopher ; Djukanovic, Ratko ; McQuaid, Douglas ; Denenberg, Michael ; Ettinger, Neil A ; Iyer, Vivek ; Smith, Jaclyn A ; Kitt, Michael M ; Morice, Alyn H ; Birring, Surinder S ; McGarvey, Lorcan P ; Sher, Mandel R ; Li, Yu-Ping ; Wu, Wen-Chi ; Xu, Zhi Jin ; Muccino, David R ; Ford, Anthony P
Source
In The Lancet Respiratory Medicine August 2020 8(8):775-785
Subject
Primary Research Articles
Language
ISSN
2213-2600